Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)
Phase 3
Completed
- Conditions
- Type 2 Diabetes MellitusHypercholesterolemia
- First Posted Date
- 2005-05-10
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1229
- Registration Number
- NCT00110435
A Study to Evaluate the Effects of Ezetimibe (MK-0653) on the Postprandial (Following a Meal) Lipoprotein Response in Participants With Primary Hypercholesterolemia (High Cholesterol) (MK-0653-072)(COMPLETED)
- First Posted Date
- 2005-01-11
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 58
- Registration Number
- NCT00101439
Safety and Efficacy of an Investigational Drug Versus Placebo in the Treatment of Cancer Pain (0663-083)
Phase 2
Withdrawn
- Conditions
- Bone Neoplasms
- First Posted Date
- 2004-11-01
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Registration Number
- NCT00095017
Study to Test an Approved Product in the Early Treatment of Migraine (0462-066)
Phase 3
Completed
- Conditions
- Migraine
- First Posted Date
- 2004-11-01
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 167
- Registration Number
- NCT00095004
A Study to Evaluate an Investigational Drug in Patients With Mixed Hyperlipidemia (0653A-071)(COMPLETED)
Phase 3
Completed
- Conditions
- HyperlipidemiaHypercholesterolemiaHypertriglyceridemia
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 611
- Registration Number
- NCT00093899
Investigation of Intravenous (IV) Administration of an Approved Drug (MK-0476, Montelukast Sodium) for Acute Asthma (MK-0476-288)
- First Posted Date
- 2004-09-29
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 650
- Registration Number
- NCT00092989
Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)
Phase 3
Completed
- Conditions
- Migraine
- First Posted Date
- 2004-09-29
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 529
- Registration Number
- NCT00092963
Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036)
Phase 3
Completed
- Conditions
- HypercholesterolemiaHypertriglyceridemia
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 587
- Registration Number
- NCT00092560
Sitosterolemia Extension Study (0653-003)(COMPLETED)
Phase 3
Completed
- Conditions
- Lipid Metabolism, Inborn ErrorsHeart Disease
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 37
- Registration Number
- NCT00092807
An Investigational Drug in Patients With Osteoarthritis (0663-073)
Phase 3
Completed
- Conditions
- Osteoarthritis
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 548
- Registration Number
- NCT00092755
© Copyright 2025. All Rights Reserved by MedPath